Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nilmary Grafals-Ruiz"'
Autor:
Luis E. Velázquez-Vega, Michael Rivera-Robles, Annelis O. Sánchez-Álvarez, Pablo E. Vivas-Mejía, Miciely Aponte-Reyes, Ailed M. Cruz-Collazo, Nilmary Grafals-Ruiz, Stephanie Dorta-Estremera, Eliud Hernández-O'Farrill, Cornelis P Vlaar, Suranganie Dharmawardhane
Publikováno v:
Translational Oncology, Vol 44, Iss , Pp 101928- (2024)
Trastuzumab and trastuzumab-based treatments are the standard of care for breast cancer patients who overexpress the human epidermal growth factor receptor 2 (HER2). However, patients often develop resistance to trastuzumab via signaling from alterna
Externí odkaz:
https://doaj.org/article/08593e49e06c4c999cc8684c83fb0cd2
Autor:
Ámbar M. Alsina-Sánchez, Sebastián Montalvo-Vázquez, Nilmary Grafals-Ruiz, Carmen Acosta, Emily M. Ormé, Israel Rodríguez, Sara M. Delgado-Rivera, Arthur D. Tinoco, Suranganie Dharmawardhane, Ingrid C. Montes-González
Publikováno v:
ACS Omega, Vol 8, Iss 38, Pp 34377-34387 (2023)
Externí odkaz:
https://doaj.org/article/f0555909e260411e907a3d345c1e20ab
Autor:
Nilmary Grafals-Ruiz, Annelis O. Sánchez-Álvarez, Yasmarie Santana-Rivera, Eunice L. Lozada-Delgado, Robert J. Rabelo-Fernandez, Christian I. Rios-Vicil, Fatima Valiyeva, Pablo E. Vivas-Mejia
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionGlioblastoma (GBM) is a highly aggressive and lethal primary brain tumor. Despite limited treatment options, the overall survival of GBM patients has shown minimal improvement over the past two decades. Factors such as delayed cancer diag
Externí odkaz:
https://doaj.org/article/729159b29ebf449a8320808f42799637
Autor:
Luis D. Borrero-García, Maria del Mar Maldonado, Julia Medina-Velázquez, Angel L. Troche-Torres, Luis Velazquez, Nilmary Grafals-Ruiz, Suranganie Dharmawardhane
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or intrinsic resistance often confounds therapy success. Common mechanisms of the
Externí odkaz:
https://doaj.org/article/89c303d0b4fe4bbeb7e582a96f5fc985
Autor:
Annelis Odette Sanchez-Alvarez, Nilmary Grafals-Ruiz, Yasmarie Santana-Rivera, Fatma Valiyeva, Nathaly M. Rosado-Rivera, Pablo E. Vivas-Mejía
Publikováno v:
Cancer Research. 83:2538-2538
MicroRNA (miRNA) dysregulation plays a central role in the initiation, progression, and drug resistance of virtually all cancer types. MiRNA-based therapies are a promising therapeutic modality against most malignancies. MiR-92b is aberrantly abundan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad8aa3ab065c334798cd5f3aa395057b
https://doi.org/10.1158/1538-7445.am2023-2538
https://doi.org/10.1158/1538-7445.am2023-2538
Publikováno v:
The FASEB Journal. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dce3c7db420a99d5e6634afea54c95a
https://doi.org/10.1096/fasebj.2022.36.s1.l7899
https://doi.org/10.1096/fasebj.2022.36.s1.l7899
Autor:
Gabriel Martínez-Zayas, Ginette S Santiago-Sánchez, Fatma Valiyeva, Yasmarie Santana-Rivera, Eunice L Lozada-Delgado, Pablo E. Vivas-Mejia, Ricardo A Noriega-Rivera, Nilmary Grafals-Ruiz, Blanca I Quiñones-Díaz, Christian I. Ríos-Vicil
Publikováno v:
International Journal of Nanomedicine. 15:2809-2828
Introduction Glioblastoma (GBM) is the most common and lethal of the central nervous system (CNS) malignancies. The initiation, progression, and infiltration ability of GBMs are attributed in part to the dysregulation of microRNAs (miRNAs). Thus, tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8b69730ae3fdd5fb79d28dad9a160d8
https://doi.org/10.2147/ijn.s241055
https://doi.org/10.2147/ijn.s241055
Autor:
Nilmary Grafals-Ruiz, Ailed M. Cruz-Collazo, Anamaris Torres-Sánchez, Surangani Dharmawardhane
Publikováno v:
Cancer Research. 83:P2-01
Triple-negative breast cancer (TNBC) is an aggressive and recurrent type of breast cancer that accounts for over 15% of new diagnoses yearly. Patients with TNBC have limited response to hormonal or targeted therapies due to the lack of ER, PR, and HE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9f5c90f42eda9754ff2e924ca29435b
https://doi.org/10.1158/1538-7445.sabcs22-p2-01-05
https://doi.org/10.1158/1538-7445.sabcs22-p2-01-05
Autor:
Julia Medina-Velázquez, Luis D. Borrero-Garcia, Maria Del Mar Maldonado, Angel L. Troche-Torres, Nilmary Grafals-Ruiz, Suranganie Dharmawardhane, Luis Velazquez
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c333ff35796383af44cb5fe118d6f0b
https://doi.org/10.21203/rs.3.rs-86620/v1
https://doi.org/10.21203/rs.3.rs-86620/v1
Autor:
Nilmary, Grafals-Ruiz, Christian I, Rios-Vicil, Eunice L, Lozada-Delgado, Blanca I, Quiñones-Díaz, Ricardo A, Noriega-Rivera, Gabriel, Martínez-Zayas, Yasmarie, Santana-Rivera, Ginette S, Santiago-Sánchez, Fatma, Valiyeva, Pablo E, Vivas-Mejía
Publikováno v:
International Journal of Nanomedicine
Introduction Glioblastoma (GBM) is the most common and lethal of the central nervous system (CNS) malignancies. The initiation, progression, and infiltration ability of GBMs are attributed in part to the dysregulation of microRNAs (miRNAs). Thus, tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::53a14f5780dbefa7d2abcfd77255bb4f
https://pubmed.ncbi.nlm.nih.gov/32368056
https://pubmed.ncbi.nlm.nih.gov/32368056